154 related articles for article (PubMed ID: 32431020)
1. The treatment rate of erectile dysfunction (ED) in younger men with type 2 diabetes is up to four times higher than the equivalent non-diabetes population.
Stedman M; Whyte MB; Lunt M; Albanese M; Livingston M; Gadsby R; Hackett G; Anderson SG; Heald AH
Int J Clin Pract; 2020 Sep; 74(9):e13538. PubMed ID: 32431020
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Scaglione F; Donde S; Hassan TA; Jannini EA
Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
[TBL] [Abstract][Full Text] [Related]
3. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
4. Exploring the association between erectile rigidity and treatment adherence with sildenafil.
Mazzola CR; Deveci S; Teloken P; Mulhall JP
J Sex Med; 2013 Jul; 10(7):1861-6. PubMed ID: 23253943
[TBL] [Abstract][Full Text] [Related]
5. New treatment options for erectile dysfunction in patients with diabetes mellitus.
Basu A; Ryder RE
Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369
[TBL] [Abstract][Full Text] [Related]
6. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation.
Carvalheira AA; Pereira NM; Maroco J; Forjaz V
J Sex Med; 2012 Sep; 9(9):2361-9. PubMed ID: 22616766
[TBL] [Abstract][Full Text] [Related]
7. Delay in seeking medical help in patients with new-onset erectile dysfunction remained high over and despite the PDE5 era--an ecological study.
Salonia A; Ferrari M; Saccà A; Pellucchi F; Castagna G; Clementi MC; Matloob R; Briganti A; Rigatti P; Montorsi F
J Sex Med; 2012 Dec; 9(12):3239-46. PubMed ID: 23057479
[TBL] [Abstract][Full Text] [Related]
8. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
[TBL] [Abstract][Full Text] [Related]
9. Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.
Zamorano-León JJ; Olivier C; de Las Heras N; Mateos-Cáceres PJ; Brime Menéndez R; Rodríguez-Sierra P; Martín Palacios N; Manso LS; Modrego J; Segura A; Macaya C; López-Farré AJ
J Sex Med; 2013 Dec; 10(12):3110-20. PubMed ID: 24112450
[TBL] [Abstract][Full Text] [Related]
10. PDE5 inhibitors: targeting erectile dysfunction in diabetics.
Francis SH; Corbin JD
Curr Opin Pharmacol; 2011 Dec; 11(6):683-8. PubMed ID: 21924956
[TBL] [Abstract][Full Text] [Related]
11. A systematic review assessing the economic impact of sildenafil citrate (Viagra) in the treatment of erectile dysfunction.
Martin AL; Huelin R; Wilson D; Foster TS; Mould JF
J Sex Med; 2013 May; 10(5):1389-400. PubMed ID: 23347555
[TBL] [Abstract][Full Text] [Related]
12. Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies.
Phé V; Rouprêt M
Diabetes Metab; 2012 Feb; 38(1):1-13. PubMed ID: 22056307
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.
Nunes AP; Seeger JD; Stewart A; Gupta A; McGraw T
J Sex Med; 2021 Sep; 18(9):1511-1523. PubMed ID: 34389264
[TBL] [Abstract][Full Text] [Related]
14. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
15. Effect of chronic administration of PDE5 combined with glycemic control on erectile function in streptozotocin-induced diabetic rats.
Choi WS; Kwon OS; Cho SY; Paick JS; Kim SW
J Sex Med; 2015 Mar; 12(3):600-10. PubMed ID: 25411013
[TBL] [Abstract][Full Text] [Related]
16. Erectile dysfunction, phosphodiesterase-5 inhibitor use and risk of cardiovascular disease and mortality in people with diabetes: A systematic review and meta-analysis.
Seidu S; Cebrián A; Kunutsor SK; Khunti K
Prim Care Diabetes; 2022 Oct; 16(5):601-613. PubMed ID: 36114105
[TBL] [Abstract][Full Text] [Related]
17. Decision tree analyses of key patient characteristics in Middle Eastern/North African and Latin American men treated with long-acting and short-acting PDE5 inhibitors for erectile dysfunction.
Rubio-Aurioles E; El-Meliegy A; Abdulwahed S; Henneges C; Sorsaburu S; Gurbuz S
Curr Med Res Opin; 2015 Feb; 31(2):367-78. PubMed ID: 25068906
[TBL] [Abstract][Full Text] [Related]
18. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction.
Fisher WA; Rosen RC; Eardley I; Niederberger C; Nadel A; Kaufman J; Sand M
J Sex Med; 2004 Sep; 1(2):150-60. PubMed ID: 16422969
[TBL] [Abstract][Full Text] [Related]
19. A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction.
Hansen SA; Aas E; Solli O
Eur J Health Econ; 2020 Feb; 21(1):73-84. PubMed ID: 31512069
[TBL] [Abstract][Full Text] [Related]
20. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.
Sung HH; Ahn JS; Kim JJ; Choo SH; Han DH; Lee SW
Andrology; 2014 Jan; 2(1):45-50. PubMed ID: 24194017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
